Apellis Pharmaceuticals, Inc. (APLS) Stock

APLS logo

Apellis Pharmaceuticals, Inc.

APLS
Healthcare

Company profile

Apellis Pharmaceuticals reported revenue of $1.00 billion for fiscal year 2025. Our analysis of its filings shows revenue growing from $396.59 million in fiscal year 2023 to $1.00 billion in fiscal year 2025, 59.1% a year on average.

What stands out

  • Revenue rose 28.5% in fiscal year 2025, from $781.37 million in fiscal year 2024, after a rise of 97.0% the year before.
  • It returned to a profit in fiscal year 2025, $22.39 million, after 4 years of net losses ($197.88 million in fiscal year 2024).
  • It spent $295.85 million on research and development in fiscal year 2025, 29.5% of its revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

Largest shareholders

  • Wellington Management Co. LLP10.89%
  • Morningside Group Ltd.10.14%
  • Avoro Capital Advisor LLC9.68%
  • EcoR1 Capital, LLC9.42%
  • Morgan Stanley Investment Management, Inc.7.72%

Share of the company, as of November 8, 2025

How much revenue does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals reported $1.00 billion in revenue for fiscal year 2025, up 28.5% from $781.37 million in fiscal year 2024.

What companies are similar to Apellis Pharmaceuticals?

Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Regeneron Pharmaceuticals, Inc. (REGN), Bausch + Lomb Corporation (BLCO), Kodiak Sciences Inc. (KOD), Belite Bio, Inc (BLTE).

How has Apellis Pharmaceuticals' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, $66.56 million; FY2022, $75.42 million; FY2023, $396.59 million; FY2024, $781.37 million; FY2025, $1.00 billion.

Has Apellis Pharmaceuticals made a profit in recent years?

Net income by fiscal year: FY2021, a loss of $746.35 million; FY2022, a loss of $652.17 million; FY2023, a loss of $528.63 million; FY2024, a loss of $197.88 million; FY2025, $22.39 million. It reported a net loss in 4 of these 5 years.

Company Information

SectorHealthcare
IndustryEye Treatment Pharmaceuticals
Founded2008
IPO DateNov 9, 2017
IPO StatusPublic
FoundersCedric Francois, Pascal Deschatelets
ExchangeNasdaqGM
TimezoneAmerica/New_York (EST)

Contact & Links

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Apellis Pharmaceuticals, Inc. (APLS)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/APLS

LinkedInLinkedInXXYouTubeYouTube